🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Zhengye Biotechnology Holding Limited ZYBT

Healthcare · Drug Manufacturers - Specialty & Generic · China
https://www.jlzybio.com
Company Profile ↓
$1.33
-74.91% 1Y
Mkt Cap$63.03M
P/E-6.05
P/B1.45
52W High$12.66
52W Low$0.65
Book Value$0.91
EPS (TTM)$-0.22

Company Overview

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.24.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $116.36M (-37.6% YoY); net profit $-69.78M.
  • Trailing 12 Months Year-on-year growth — revenue -40.9%, earnings -717.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -23.5%, profit CAGR -83.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-23.53%
1 Year:-40.90%

Compounded Profit Growth

5 Years:-83.11%
1 Year:-716.96%

Stock Price Performance

1 Year:-74.91%
6 Months:+41.34%
3 Months:+44.57%
1 Month:+96.45%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 6% of range
$0.65 $12.66
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)49.48 · Neutral
Price Performance
1M+96.45%
3M+44.57%
6M+41.34%
1Y-74.91%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Revenue declined at -23.5% CAGR over 5 years.
  • Earnings shrank at -83.1% CAGR over 5 years.
  • Trading 89.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-6.05
Industry PE
27.41
Forward P/E
-
PEG Ratio
-
Book Value
$0.91
Price to Book
1.45
P/S
0.54
EV/EBITDA
-3.21
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-23.53%
Profit 5Y
-83.11%
Revenue (YoY)
-40.90%
Earnings (YoY)
-716.96%

Profitability & Returns

ROCE
-21.67%
ROE
-25.17%
ROA
-9.48%
Profit Margin
-59.97%
Op Margin
-77.04%
Gross Margin
20.51%
EPS (Latest Qtr)
$-
EPS (TTM)
$-0.22

Balance Sheet & Liquidity

Debt/Equity
0.24
Quick Ratio
0.58
Current Ratio
1.14
Debt
$75.08M
Total Assets
$436.47M
Current Assets
$137.42M
Working Capital
$16.94M

Ownership

Promoter Holding
16.16%
Chg in Prom Hold
-
FII / Inst Holding
1.10%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$143.09M
Total Revenue (TTM)
$116.36M
EBITDA
$-44.62M
Free Cash Flow
$39.58M
Operating Cash Flow
$13.33M
Shares Outstanding
47.39M
Gross Margin
20.51%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ZYBT Zhengye Biotechnology Holding Limited 1.33 -6.05 $63.03M 0.00% -21.67% -25.17% -23.53% -83.11%
2 LLY Eli Lilly and Company SPX 1,148.84 40.85 $1.02T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 256.35 29.74 $617.09B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 250.94 122.41 $443.36B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 414.40 31.23 $376.34B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 130.20 36.68 $321.57B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 169.64 26.30 $263.09B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 574.30 31.54 $213.42B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 385.16 26.78 $207.87B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -260.27M211.65M186.36M116.36M
Cost of Revenue -112.39M94.14M95.06M92.49M
Gross Profit -147.88M117.51M91.30M23.87M
Operating Expenses -81.79M69.87M74.12M92.12M
Operating Income -66.09M47.64M17.17M-68.25M
EBITDA -85.55M72.10M42.60M-42.52M
Interest Expense -2.84M4.42M4.04M3.40M
Pretax Income -63.91M43.76M14.39M-71.87M
Tax Provision -8.17M6.25M924.00K11.10M
Net Income -46.73M31.46M11.31M-69.78M
Diluted EPS 0.830.990.670.24-

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -519.67M499.89M493.25M436.47M
Current Assets -214.31M189.24M177.57M137.42M
Cash & Equivalents -9.75M15.07M18.60M50.33M
Inventory -55.42M58.30M58.22M39.17M
Receivables -102.90M74.17M59.56M18.48M
Total Liabilities -162.81M160.62M140.71M129.76M
Current Liabilities -152.23M150.23M135.91M120.48M
Long Term Debt -9.99M9.99M4.80M8.85M
Total Debt -64.88M89.85M86.43M75.08M
Total Equity -296.50M272.85M283.96M249.85M
Shares Outstanding -47.17M47.17M47.17M47.39M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -17.34M48.18M41.05M13.33M
Investing Cash Flow --27.33M-11.77M-27.66M-12.63M
Financing Cash Flow -13.46M-18.98M-22.13M32.31M
Capital Expenditure --27.33M-11.60M-27.77M-12.63M
Free Cash Flow --9.99M36.58M13.27M703.00K
Net Change in Cash -3.46M17.44M-8.75M33.01M

Ratios (Annual)

Figures in %.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -56.8%55.5%49.0%20.5%
Operating Margin % -25.4%22.5%9.2%-58.7%
Net Margin % -18.0%14.9%6.1%-60.0%
ROE % -15.8%11.5%4.0%-27.9%
ROCE % -18.0%13.6%4.8%-21.6%

Shareholding Pattern

Insiders
16.16%
Institutions
1.10%
Public Float
1.32%

Top Institutional Holders

#Holder% HeldSharesValue
1 Xtx Topco Ltd 0.09% 44.15K $58.71K
2 Winton Group Ltd 0.07% 33.39K $44.41K
3 Geode Capital Management, LLC 0.06% 29.07K $38.66K
4 UBS Group AG 0.02% 8.04K $10.69K
5 Tower Research Capital LLC (TRC) 0.01% 4.91K $6.53K
6 Caitong International Asset Management Co., Ltd - 1 $1
7 Royal Bank of Canada - 1.23K $1.64K
8 Morgan Stanley - 261 $347

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZYBT

No recent headlines available.

ZYBT — Frequently Asked Questions

What is the current share price of Zhengye Biotechnology Holding Limited (ZYBT)?

As of 2026-08-02 19:16 PDT, Zhengye Biotechnology Holding Limited (ZYBT) trades at $1.33 on NasdaqCM. Its 52-week range is $0.65 to $12.66.

What is the market capitalisation of ZYBT?

Zhengye Biotechnology Holding Limited (ZYBT) has a market capitalisation of $63.03M on NasdaqCM.

What is the P/E ratio of ZYBT?

ZYBT trades at a trailing price-to-earnings (P/E) ratio of -6.05. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 1.45.

What is the return on equity (ROE) of ZYBT?

ZYBT has a return on equity (ROE) of -25.17%. Its return on capital employed (ROCE) is -21.67%.

Is ZYBT a good stock to buy?

This page provides a data-driven analysis of Zhengye Biotechnology Holding Limited (ZYBT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space